The trial achieved each its Major endpoints, with semaglutide two.four mg demonstrating statistically sizeable and outstanding advancements in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis without any worsening of liver fibrosis in people with MASH in comparison with placebo.oneExcretion The primary e… Read More